Xiamen University Affiliated Xiamen Eye Center, Fujian Provincial Key Laboratory of Ophthalmology and Visual Science, Fujian Engineering and Research Center of Eye Regenerative Medicine, Eye Institute of Xiamen University, School of Medicine, Xiamen University, Xiamen, Fujian, China.
Department of Ophthalmology, The First Affiliated Hospital of University of South China, Hengyang, Hunan, China.
Transl Vis Sci Technol. 2024 Sep 3;13(9):17. doi: 10.1167/tvst.13.9.17.
This study aimed to assess the drug risk of drug-related keratitis and track the epidemiological characteristics of drug-related keratitis.
This study analyzed data from the U.S. Food and Drug Administration (FDA) Adverse Event Reporting System (FAERS) database from January 2004 to December 2023. A disproportionality analysis was conducted to assess drug-related keratitis with positive signals, and drugs were classified and assessed with regard to their drug-induced timing and risk of drug-related keratitis.
A total of 1606 drugs were reported to pose a risk of drug-related keratitis in the FAERS database, and, after disproportionality analysis and screening, 17 drugs were found to significantly increase the risk of drug-related keratitis. Among them, seven were ophthalmic medications, including dorzolamide (reporting odds ratio [ROR] = 3695.82), travoprost (ROR = 2287.27), and brimonidine (ROR = 2118.52), and 10 were non-ophthalmic medications, including tralokinumab (ROR = 2609.12), trazodone (ROR = 2377.07), and belantamab mafodotin (ROR = 680.28). The top three drugs having the highest risk of drug-related keratitis were dorzolamide (Bayesian confidence propagation neural network [BCPNN] = 11.71), trazodone (BCPNN = 11.11), and tralokinumab (BCPNN = 11.08). The drug-induced times for non-ophthalmic medications were significantly shorter than those for ophthalmic medications (mean days, 141.02 vs. 321.96, respectively; P < 0.001). The incidence of drug-related keratitis reached its peak in 2023.
Prevention of drug-related keratitis is more important than treatment. Identifying the specific risks and timing of drug-induced keratitis can support the development of preventive measures.
Identifying the specific drugs related to medication-related keratitis is of significant importance for drug vigilance in the occurrence of drug-related keratitis.
本研究旨在评估与药物相关的角膜炎的药物风险，并追踪与药物相关的角膜炎的流行病学特征。
本研究分析了 2004 年 1 月至 2023 年 12 月期间美国食品和药物管理局（FDA）不良事件报告系统（FAERS）数据库中的数据。采用比例失衡分析评估具有阳性信号的与药物相关的角膜炎，对药物进行分类，并评估其药物诱导的时间和与药物相关的角膜炎的风险。
在 FAERS 数据库中，共有 1606 种药物被报告存在与药物相关的角膜炎风险，经过比例失衡分析和筛选，发现 17 种药物显著增加了与药物相关的角膜炎的风险。其中，7 种是眼科药物，包括多佐胺（报告比值比 [ROR] = 3695.82）、曲伏前列素（ROR = 2287.27）和溴莫尼定（ROR = 2118.52），10 种是非眼科药物，包括特利鲁单抗（ROR = 2609.12）、曲唑酮（ROR = 2377.07）和贝兰他单抗mafodotin（ROR = 680.28）。与药物相关的角膜炎风险最高的三种药物分别为多佐胺（贝叶斯置信传播神经网络 [BCPNN] = 11.71）、曲唑酮（BCPNN = 11.11）和特利鲁单抗（BCPNN = 11.08）。非眼科药物的药物诱导时间明显短于眼科药物（平均天数分别为 141.02 天和 321.96 天；P < 0.001）。与药物相关的角膜炎的发生率在 2023 年达到峰值。
预防与药物相关的角膜炎比治疗更为重要。确定药物诱导性角膜炎的具体风险和时间可以支持预防措施的制定。
本译文仅供参考，如有不当之处，请以原文为准。
Zotero 插件
